Solomon Langermann

6.0k total citations · 2 hit papers
55 papers, 4.0k citations indexed

About

Solomon Langermann is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Solomon Langermann has authored 55 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 18 papers in Oncology and 12 papers in Epidemiology. Recurrent topics in Solomon Langermann's work include Cancer Immunotherapy and Biomarkers (12 papers), Escherichia coli research studies (11 papers) and Immunotherapy and Immune Responses (8 papers). Solomon Langermann is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Escherichia coli research studies (11 papers) and Immunotherapy and Immune Responses (8 papers). Solomon Langermann collaborates with scholars based in United States, Greece and Sweden. Solomon Langermann's co-authors include Jerome S. Pinkner, Scott J. Hultgren, Devapriya Choudhury, Stefan D. Knight, Susan Palaszynski, Scott Koenig, John E. Adamou, Andrew W. Thompson, V. Stojanoff and Theresa M. Wizemann and has published in prestigious journals such as Nature, Science and Journal of Clinical Investigation.

In The Last Decade

Solomon Langermann

53 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

X-ray Structure of the FimC-FimH Chaperone-Adhesin Complex from Uropathogenic Escherichia coli

1999 504 citations Devapriya Choudhury, Solomon Langermann et al. profile →
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

2019 488 citations Jun Wang, Jingwei Sun et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Solomon Langermann United States	27	1.7k	1.0k	984	911	564	55	4.0k
Craig Cummings United States	32	971 0.6×	359 0.4×	477 0.5×	705 0.8×	532 0.9×	52	3.3k
Partho Ghosh United States	37	2.2k 1.3×	1.3k 1.3×	383 0.4×	737 0.8×	201 0.4×	79	4.9k
Robert S. Munson United States	44	1.8k 1.1×	478 0.5×	1.8k 1.8×	654 0.7×	405 0.7×	115	5.3k
Katherine Makepeace United Kingdom	28	1.1k 0.6×	614 0.6×	914 0.9×	364 0.4×	231 0.4×	44	2.9k
Nicklas Strömberg Sweden	34	1.8k 1.1×	565 0.6×	448 0.5×	821 0.9×	140 0.2×	71	3.6k
Mumtaz Virji United Kingdom	42	1.8k 1.1×	985 1.0×	1.7k 1.7×	596 0.7×	610 1.1×	104	5.6k
Irma van Die Netherlands	38	2.8k 1.7×	1.3k 1.3×	418 0.4×	700 0.8×	178 0.3×	77	4.3k
Christine Hale United Kingdom	31	1.0k 0.6×	901 0.9×	706 0.7×	496 0.5×	210 0.4×	71	3.3k
Susann Teneberg Sweden	36	1.9k 1.1×	1.9k 1.9×	583 0.6×	752 0.8×	229 0.4×	112	4.6k
Travis Beddoe Australia	41	1.7k 1.0×	3.7k 3.7×	717 0.7×	375 0.4×	830 1.5×	134	6.3k

Countries citing papers authored by Solomon Langermann

Since Specialization

Citations

This map shows the geographic impact of Solomon Langermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solomon Langermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solomon Langermann more than expected).

Fields of papers citing papers by Solomon Langermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solomon Langermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solomon Langermann. The network helps show where Solomon Langermann may publish in the future.

Co-authorship network of co-authors of Solomon Langermann

This figure shows the co-authorship network connecting the top 25 collaborators of Solomon Langermann. A scholar is included among the top collaborators of Solomon Langermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solomon Langermann. Solomon Langermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lovewell, Rustin R., Solomon Langermann, & Dallas B. Flies. (2025). Immune inhibitory receptor agonist therapeutics. Frontiers in Immunology. 16. 1566869–1566869. 2 indexed citations

Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538. 2 indexed citations

Yan, Chuan, Qiqi Yang, Daniel P. Fitzgerald, et al.. (2024). The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies. Science Advances. 10(9). eadj4698–eadj4698. 1 indexed citations

Aung, Thazin Nwe, Niki Gavrielatou, Aileen I. Fernandez, et al.. (2023). Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer. Cancer Research Communications. 3(3). 471–482. 2 indexed citations

Rabe, Jennifer L., Chengjing Zhou, Deborah DeRyckere, et al.. (2023). Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Research Communications. 3(7). 1248–1259. 4 indexed citations

Flies, Dallas B., Solomon Langermann, Christina Jensen, M.A. Karsdal, & Nicholas Willumsen. (2023). Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix. Frontiers in Immunology. 14. 1199513–1199513. 40 indexed citations

Peng, Yuanzhen, Solomon Langermann, Linda Liu, et al.. (2023). Anti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats. JBMR Plus. 7(12). e10825–e10825. 2 indexed citations

Wang, Jun, Jingwei Sun, Linda N. Liu, et al.. (2019). Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine. 25(4). 656–666. 488 indexed citations breakdown →

Hoos, Axel, et al.. (2013). AMP-224, a Fusion Protein that Targets PD-1. Annals of Oncology. 24. i7–i7. 12 indexed citations

10.

Vargas‐Inchaustegui, Diego A., Peng Xiao, Alison Hogg, et al.. (2013). Immune targeting of PD-1hi expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology. 447(1-2). 274–284. 14 indexed citations

11.

Podojil, Joseph R., Linda N. Liu, Shannon Marshall, et al.. (2013). B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. Journal of Autoimmunity. 44. 71–81. 46 indexed citations

12.

Podoly, Erez, Sophia Diamant, Naomi Melamed‐Book, et al.. (2008). Human Recombinant Butyrylcholinesterase Purified from the Milk of Transgenic Goats Interacts with Beta-Amyloid Fibrils and Suppresses Their Formation in vitro. Neurodegenerative Diseases. 5(3-4). 232–236. 35 indexed citations

13.

Bouckaert, Julie, Jenny Berglund, Mark A. Schembri, et al.. (2004). Receptor binding studies disclose a novel class of high‐affinity inhibitors of the Escherichia coli FimH adhesin. Molecular Microbiology. 55(2). 441–455. 368 indexed citations

14.

Woods, Robert M., E. Sally Ward, Susan Palaszynski, et al.. (2002). Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences. The Journal of Immunology. 169(9). 5171–5180. 271 indexed citations

15.

Hung, Chia‐Suei, Julie Bouckaert, Danielle L. Hung, et al.. (2002). Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Molecular Microbiology. 44(4). 903–915. 325 indexed citations

16.

Langermann, Solomon & W. Ripley Ballou. (2001). Vaccination Utilizing the FimCH Complex As a Strategy to PreventEscherichia coliUrinary Tract Infections. The Journal of Infectious Diseases. 183(s1). S84–S86. 58 indexed citations

17.

Langermann, Solomon, Roland Möllby, Jeanne E. Burlein, et al.. (2000). Vaccination with FimH Adhesin Protects Cynomolgus Monkeys from Colonization and Infection by UropathogenicEscherichia coli. The Journal of Infectious Diseases. 181(2). 774–778. 255 indexed citations

18.

Wizemann, Theresa M., John E. Adamou, & Solomon Langermann. (1999). Adhesins as Targets for Vaccine Development. Emerging infectious diseases. 5(3). 395–403. 126 indexed citations

19.

Branco, Luis M., Philip Barren, Su-Yau Mao, et al.. (1999). SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS. Transplantation. 68(10). 1588–1596. 35 indexed citations

20.

Langermann, Solomon, Susan Palaszynski, Jeanne E. Burlein, et al.. (1994). Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.. The Journal of Experimental Medicine. 180(6). 2277–2286. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact